Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.

Aragão, Filipa; Vera, José; Vaz Pinto, Inês

Aragão, Filipa; Vera, José; Vaz Pinto, Inês.

Affiliation

Aragão F; Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Lisboa, Lisboa, Portugal. filipaaragao@gmail.com

PLoS One ; 7(9): e44774, 2012.

Article in En | MEDLINE | ID: mdl-23028618

Subject(s)

Anti-HIV Agents/economics; Anti-HIV Agents/therapeutic use; HIV Infections/drug therapy; HIV-1/drug effects; Reverse Transcriptase Inhibitors/economics; Reverse Transcriptase Inhibitors/therapeutic use; Adult; Anti-HIV Agents/pharmacology; CD4 Lymphocyte Count/statistics & numerical data; Cost-Benefit Analysis/statistics & numerical data; Drug Resistance, Viral; Female; HIV Infections/immunology; HIV-1/physiology; Humans; Male; Middle Aged; Models, Statistical; Patient Compliance/statistics & numerical data; Portugal; Probability; Reverse Transcriptase Inhibitors/pharmacology; Time Factors; Viral Load/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / Reverse Transcriptase Inhibitors / Anti-HIV Agents Type of study: Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2012 Type: Article Affiliation country: Portugal

Fulltext

XML

PubMed Links

Search on Google